AvenCell
Biotechnology ResearchMassachusetts, United States51-200 Employees
Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
Insights
Cutting-edge Therapy AvenCell develops next-generation immunotherapies for hard-to-treat cancers, such as the novel allogeneic CD123-directed switchable CAR-T investigational therapy. This innovative approach positions the company as a leader in the field, offering a compelling solution for patients in need of advanced treatment options.
Recent Expansions Recent announcements of EMA approval for Clinical Trial Applications and the launch of updated safety and efficacy data indicate significant progress and expansion within AvenCell. These milestones signal growth opportunities for partnerships, collaborations, and further market penetration in the biotechnology research sector.
Key Personnel Addition The appointment of Maniar as the Chief Medical Officer brings valuable expertise and leadership to AvenCell. With a strong figure heading the medical team, the company is poised to strengthen its research capabilities, explore new avenues for therapies, and potentially attract more interest from investors and collaborators.
Financial Health AvenCell's revenue ranging from $10M to $50M positions it as a financially stable player in the biotechnology research industry. This financial health not only instills trust in potential partners and investors but also indicates a capacity for sustained growth and scalability in operations.
Market Positioning Among similar companies like Genetech Solutions and HealthCell, AvenCell's focus on cutting-edge therapies, recent expansions, key personnel appointments, and solid financial standing sets it apart. Leveraging these strengths can help position AvenCell as a top choice for strategic collaborations, licensing deals, and investments within the competitive landscape.
AvenCell Tech Stack
AvenCell uses 8 technology products and services including Font Awesome, Google Cloud, Stimulus, and more. Explore AvenCell's tech stack below.
- Font AwesomeFont Scripts
- Google CloudInfrastructure As A Service
- StimulusJavascript Frameworks
- ChoicesJavascript Libraries
- jQuery MigrateJavascript Libraries
- jQueryJavascript Libraries
- SwiperJavascript Libraries
- RSSMiscellaneous
Media & News
AvenCell's Email Address Formats
AvenCell uses at least 1 format(s):
| AvenCell Email Formats | Percentage |
| First.Last@avencell.com | 48% |
| Fir.Last@avencell.com | 3% |
| FirstL@avencell.com | 1% |
| First.Last@avencell.com | 48% |
Frequently Asked Questions
Where is AvenCell's headquarters located?
AvenCell's main headquarters is located at 51 Moulton St Cambridge, Massachusetts 02138 US. The company has employees across 3 continents, including EuropeNorth AmericaAsia. What is AvenCell's official website and social media links?
AvenCell's official website is avencell.com and has social profiles on LinkedIn.How much revenue does AvenCell generate?
As of September 2024, AvenCell's annual revenue reached $15M. What is AvenCell's SIC code NAICS code?
AvenCell's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).How many employees does AvenCell have currently?
As of September 2024, AvenCell has approximately 74 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: A. S.Chief Financial Officer: B. G.Chief Scientific Officer: A. E.. Explore AvenCell's employee directory with LeadIQ.What industry does AvenCell belong to?
AvenCell operates in the Biotechnology Research industry. What technology does AvenCell use?
AvenCell's tech stack includes Font AwesomeGoogle CloudStimulusChoicesjQuery MigratejQuerySwiperRSS. What is AvenCell's email format?
AvenCell's email format typically follows the pattern of . Find more AvenCell email formats with LeadIQ. 
Company Overview
- Headquarters
- 51 Moulton St Cambridge, Massachusetts 02138 US
- Website
- avencell.com
- SIC Code
- 8733 - Noncommercial Research Organizations
- NAICS Code
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Employees
- 51-200
Media & News
Funding & Financials
- $10M$50M
AvenCell's revenue is in the range of $10M$50M
Funding & Financials
- $10M$50M
AvenCell's revenue is in the range of $10M$50M
Company Leadership
A. S.Chief Executive Officer- B. G.Chief Financial Officer
A. E.Chief Scientific Officer
J. R.Chief Human Resources Officer- M. O.Vice President Operations (us) And Global It
Employee Directory
- B. B.Director, Head Of Immuno-Oncology (us)
- A. K.Vp Of Finance And Corporate Controller
- M. O.Vice President Operations (us) And Global It
- E. K.Associate Director
- A. F.Associate Director
1-888-653-2347 
support@leadiq.com © LeadIQ, Inc. All rights reserved.
